A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- NA
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE1
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Nivolumab+Ipilimumab+RT in MSS mCRC
- Status
- UNKNOWN
- Phase
- PHASE2
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
- Status
- RECRUITING
- Phase
- PHASE1
A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors
- Status
- COMPLETED
- Phase
- PHASE2
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
- Status
- RECRUITING
- Phase
- PHASE2
Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Status
- RECRUITING
- Phase
- PHASE2
A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread
- Status
- COMPLETED
- Phase
- PHASE1
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients
- Status
- COMPLETED
- Phase
- PHASE2
A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1